Traditional but not HIV-related factors are associated with nonalcoholic fatty liver disease in asian patients with HIV-1 infection

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Nishijima, Takeshi ^a,b   Gatanaga, Hiroyuki ^a,b   Shimbo, Takuro ^a   Komatsu, Hirokazu ^c   Nozaki, Yuichi ^a   Nagata, Naoyoshi ^a   Kikuchi, Yoshimi ^a   Yanase, Mikio ^a   Oka, Shinichi ^a,b  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c Saku Central Hospital Advanced Care Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; ASIA; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; ECHOGRAPHY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; RISK FACTOR;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED;

EID: 84900315893     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087596     Document Type: Article

References (25)

1. Lazo M, Clark JM (2008) The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 28: 339-350.
2. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, et al. (2005) The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129: 113-121. (Pubitemid 41002048)
3. Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34: 274-285.
4. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, et al. (2011) Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140: 124-131.
5. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, et al. (2007) How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 22: 788-793. (Pubitemid 46911047)
6. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55: 2005-2023.
7. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, et al. (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40: 1461-1465.
8. Crum-Cianflone N, Dilay A, Collins G, Asher D, Campin R, et al. (2009) Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 50: 464-473.
9. Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, et al. (2008) Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 47: 250-257. (Pubitemid 351920629)
10. (2010) Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 50: 1387-1396.
11. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, et al. (2008) Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 48: 590-598.
12. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, et al. (2006) Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166: 1632-1641. (Pubitemid 44232373)
13. (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. The Lancet 372: 293-299.
14. Nishijima T, Komatsu H, Higasa K, Takano M, Tsuchiya K, et al. (2012) Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study. Clin Infect Dis 55: 1558-1567.
15. Tsukada K, Sugawara Y, Kaneko J, Tamura S, Tachikawa N, et al. (2011) Living donor liver transplantations in HIV- and hepatitis C virus-coinfected hemophiliacs: experience in a single center. Transplantation 91: 1261-1264.
16. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, et al. (2011) Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 54: 1082-1090.
17. Rumack CM, Wilson SR, Charboneau JW, Johnson JM (2005) Diagnostic Ultrasound. Vol 1. 3rd ed. St Louis: Elsevier Mosby.
18. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142: 1592-1609.
19. Lemoine M, Serfaty L, Capeau J (2012) From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. Curr Opin Infect Dis 25: 10-16.
20. Zeremski M, Talal AH (2006) Dideoxynucleoside analogues should be used cautiously in patients with hepatic steatosis. Clin Infect Dis 43: 373-376. (Pubitemid 44078911)
21. Farrell GC, Larter CZ (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43: S99-S112.
22. Walker UA, Bauerle J, Laguno M, Murillas J, Mauss S, et al. (2004) Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 39: 311-317. (Pubitemid 38222171)
23. Lewis W, Day BJ, Copeland WC (2003) Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2: 812-822. (Pubitemid 37361813)
24. Claessens YE, Cariou A, Monchi M, Soufir L, Azoulay E, et al. (2003) Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine. Crit Care Med 31: 1042-1047. (Pubitemid 36444411)
25. Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA (2000) Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 133: 192-196. (Pubitemid 30617057)